The UN in Indonesia hosts the Green Community Festival in Jakarta, highlighting youth-led climate solutions for World ...

More than 100 kings, sultans, and customary leaders from Indonesia and abroad are scheduled to attend the 7th Nusantara ...

An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a ...

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF ...

The second poster, “Health-Related Quality of Life in Patients Previously Treated with an EGFR-TKI from HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy” includes data from ...

ChatHarmoni plus a suite of new enhancements elevate insight discovery with assisted exploration, smarter analytics, and methodical reporting. AUCKLAND, New Zealand, March 10, 2026 /PRNewswire/ -- ...

AUCKLAND, New Zealand, March 10, 2026 /PRNewswire/ -- Infotools, a pioneer in market research analysis and reporting for over three decades, today announced the launch of Harmoni 3 (H3), the most ...

Management expects the interim PFS analysis for the HARMONi-3 squamous cohort in Q2 2026, with final PFS and interim OS data anticipated in the second half of the year. For the non-squamous cohort, ...